Drug Trial Radar · NCT01585025
Obeticholic Acid in Bile Acid Diarrhoea
Last checked: Nov 19, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Apr 2012
Primary completion
Jan 2014
Study completion Feb 2014
Sponsor
- Lead sponsor
- Imperial College Healthcare NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 25, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators propose to develop studies of obeticholic acid (OCA) in patients with bile acid diarrhoea. OCA is a semisynthetic bile acid, also known as 6αethylchenodeoxycholic acid or INT747,and is a potent farnesoid X receptor (FXR) agonist. Preliminary data suggests that patients with bile acid diarrhoea have impaired production of the ileal hormone Fibroblast Growth Factor 19 (FGF19). FGF19 is stimulated by FXR agonists, and regulates bile acid synthesis. This study is a pilot, proof-of-concept, open-label study to investigate whether OCA can stimulate FGF19 in bile acid diarrhoea patients to provide a safe and effective treatment.
Conditions
- Primary Bile Acid Malabsorption
- Secondary Bile Acid Malabsorption
- Chronic Diarrhoea
Interventions
Obeticholic acidDrug
Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in Fasting FGF19Time frame: Day 0, Day 15
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hammersmith Hospital, Imperial College Healthcare NHS Trust
London, United Kingdom
Hammersmith Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.